NCT04214093: A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with previously untreated unstable brain metastases – see trial for details; Patients with leptomeningeal disease

Comments are closed.

Up ↑